The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
Identifieur interne : 002F27 ( Istex/Corpus ); précédent : 002F26; suivant : 002F28The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
Auteurs : Coleman ; K. W. Lange ; N. P. Quinn ; A. E. Loper ; J. V. Bondi ; M. Hichens ; S. M. Stahl ; C. D. MarsdenSource :
- Movement Disorders [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
Abstract
(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.
Url:
DOI: 10.1002/mds.870040204
Links to Exploration step
ISTEX:CDB145AA1E9A01CCC106745F8337B15DA7C6FA44Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><author><name sortKey="Coleman" sort="Coleman" uniqKey="Coleman" last="Coleman">Coleman</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K. W." last="Lange">K. W. Lange</name><affiliation><mods:affiliation>The Institute of Psychiatry, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation><affiliation><mods:affiliation>The Institute of Psychiatry, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A. E." last="Loper">A. E. Loper</name><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J. V." last="Bondi">J. V. Bondi</name><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M." last="Hichens">M. Hichens</name><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040204</idno><idno type="url">https://api.istex.fr/document/CDB145AA1E9A01CCC106745F8337B15DA7C6FA44/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><author><name sortKey="Coleman" sort="Coleman" uniqKey="Coleman" last="Coleman">Coleman</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K. W." last="Lange">K. W. Lange</name><affiliation><mods:affiliation>The Institute of Psychiatry, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation><affiliation><mods:affiliation>The Institute of Psychiatry, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A. E." last="Loper">A. E. Loper</name><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J. V." last="Bondi">J. V. Bondi</name><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M." last="Hichens">M. Hichens</name><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation><affiliation><mods:affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation><mods:affiliation>The Institute of Neurology, London, U.K.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="138">138</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</idno><idno type="DOI">10.1002/mds.870040204</idno><idno type="ArticleID">MDS870040204</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine</term><term>Dopamine agonist</term><term>On‐off fluctuations</term><term>Parkinson's disease</term><term>Transdermal drug delivery</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Coleman</name><affiliations><json:string>The Institute of Neurology, London, U.K.</json:string></affiliations></json:item><json:item><name>K. W. Lange</name><affiliations><json:string>The Institute of Psychiatry, London, U.K.</json:string></affiliations></json:item><json:item><name>N. P. Quinn</name><affiliations><json:string>The Institute of Neurology, London, U.K.</json:string><json:string>The Institute of Psychiatry, London, U.K.</json:string></affiliations></json:item><json:item><name>A. E. Loper</name><affiliations><json:string>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</json:string></affiliations></json:item><json:item><name>J. V. Bondi</name><affiliations><json:string>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</json:string></affiliations></json:item><json:item><name>M. Hichens</name><affiliations><json:string>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</json:string></affiliations></json:item><json:item><name>S. M. Stahl</name><affiliations><json:string>The Institute of Neurology, London, U.K.</json:string><json:string>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</json:string></affiliations></json:item><json:item><name>C. D. Marsden</name><affiliations><json:string>The Institute of Neurology, London, U.K.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>On‐off fluctuations</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Transdermal drug delivery</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine</value></json:item></subject><language><json:string>eng</json:string></language><abstract>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.</abstract><qualityIndicators><score>4.089</score><pdfVersion>1.3</pdfVersion><pdfPageSize>486 x 720.24 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>731</abstractCharCount><pdfWordCount>2733</pdfWordCount><pdfCharCount>15894</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>113</abstractWordCount></qualityIndicators><title>The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><genre><json:string>Serial article</json:string></genre><host><volume>4</volume><pages><total>10</total><last>138</last><first>129</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1002/mds.870040204</json:string></doi><id>CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/CDB145AA1E9A01CCC106745F8337B15DA7C6FA44/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/CDB145AA1E9A01CCC106745F8337B15DA7C6FA44/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/CDB145AA1E9A01CCC106745F8337B15DA7C6FA44/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><author><persName><surname>Coleman</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, The London Hospital, Whitechapel, London E1 1BB, U.K.</p></note><affiliation>The Institute of Neurology, London, U.K.</affiliation></author><author><persName><forename type="first">K. W.</forename><surname>Lange</surname></persName><affiliation>The Institute of Psychiatry, London, U.K.</affiliation></author><author><persName><forename type="first">N. P.</forename><surname>Quinn</surname></persName><affiliation>The Institute of Neurology, London, U.K.</affiliation><affiliation>The Institute of Psychiatry, London, U.K.</affiliation></author><author><persName><forename type="first">A. E.</forename><surname>Loper</surname></persName><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation></author><author><persName><forename type="first">J. V.</forename><surname>Bondi</surname></persName><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation></author><author><persName><forename type="first">M.</forename><surname>Hichens</surname></persName><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation></author><author><persName><forename type="first">S. M.</forename><surname>Stahl</surname></persName><affiliation>The Institute of Neurology, London, U.K.</affiliation><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation></author><author><persName><forename type="first">C. D.</forename><surname>Marsden</surname></persName><affiliation>The Institute of Neurology, London, U.K.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989"></date><biblScope unit="vol">4</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="138">138</biblScope></imprint></monogr><idno type="istex">CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</idno><idno type="DOI">10.1002/mds.870040204</idno><idno type="ArticleID">MDS870040204</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>On‐off fluctuations</term></item><item><term>Transdermal drug delivery</term></item><item><term>Dopamine agonist</term></item><item><term>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/CDB145AA1E9A01CCC106745F8337B15DA7C6FA44/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v4:2</doi><numberingGroup><numbering type="journalVolume" number="4">4</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="1989">1989</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="4" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870040204</doi><idGroup><id type="unit" value="MDS870040204"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1989 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.18.1 mode:FullText source:HeaderRef result:HeaderRef" date="2010-09-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">129</numbering><numbering type="pageLast">138</numbering></numberingGroup><correspondenceTo>Department of Neurology, The London Hospital, Whitechapel, London E1 1BB, U.K.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870040204.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="13"></count></countGroup><titleGroup><title type="main" xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><title type="short" xml:lang="en">TRANSDERMAL + PHNO</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>R. J.</givenNames><familyName>Coleman</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>K. W.</givenNames><familyName>Lange</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>N. P.</givenNames><familyName>Quinn</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>A. E.</givenNames><familyName>Loper</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>J. V.</givenNames><familyName>Bondi</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>M.</givenNames><familyName>Hichens</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>S. M.</givenNames><familyName>Stahl</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>C. D.</givenNames><familyName>Marsden</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>The Institute of Neurology, London, U.K.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>The Institute of Psychiatry, London, U.K.</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">On‐off fluctuations</keyword><keyword xml:id="kwd3">Transdermal drug delivery</keyword><keyword xml:id="kwd4">Dopamine agonist</keyword><keyword xml:id="kwd5">(+)‐4‐Propyl‐9‐hydroxynaphthoxazine</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>TRANSDERMAL + PHNO</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Coleman</namePart><affiliation>The Institute of Neurology, London, U.K.</affiliation><description>Correspondence: Department of Neurology, The London Hospital, Whitechapel, London E1 1BB, U.K.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K. W.</namePart><namePart type="family">Lange</namePart><affiliation>The Institute of Psychiatry, London, U.K.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N. P.</namePart><namePart type="family">Quinn</namePart><affiliation>The Institute of Neurology, London, U.K.</affiliation><affiliation>The Institute of Psychiatry, London, U.K.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. E.</namePart><namePart type="family">Loper</namePart><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. V.</namePart><namePart type="family">Bondi</namePart><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Hichens</namePart><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. M.</namePart><namePart type="family">Stahl</namePart><affiliation>The Institute of Neurology, London, U.K.</affiliation><affiliation>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. D.</namePart><namePart type="family">Marsden</namePart><affiliation>The Institute of Neurology, London, U.K.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1989</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">6</extent><extent unit="tables">1</extent><extent unit="references">13</extent></physicalDescription><abstract lang="en">(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>On‐off fluctuations</topic><topic>Transdermal drug delivery</topic><topic>Dopamine agonist</topic><topic>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>129</start><end>138</end><total>10</total></extent></part></relatedItem><identifier type="istex">CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</identifier><identifier type="DOI">10.1002/mds.870040204</identifier><identifier type="ArticleID">MDS870040204</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1989 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002F27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:CDB145AA1E9A01CCC106745F8337B15DA7C6FA44
|texte= The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
}}
| This area was generated with Dilib version V0.6.23. |  |